Overview

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Status:
Completed

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy before radiation therapy, and combining chemotherapy with radiation therapy, may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of neoadjuvant gemcitabine, paclitaxel, and carboplatin followed by cisplatin and radiation therapy in treating patients who have locally advanced or recurrent carcinoma (cancer) of the urothelium.

Phase:

Phase 2

Details

Lead Sponsor:

Southwest Oncology Group

Collaborator:

National Cancer Institute (NCI)

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Gemcitabine
Paclitaxel